Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.33 |
| ▸ | RXRA | P19793 | 3/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19386039 | 0.92 | USP30 (0.37) | USP30NR1H2RXRANR1H3CTSD | |
| SCHEMBL19582976 | 0.92 | USP30 (0.37) | USP30NR1H2RXRANR1H3CTSD | |
| SCHEMBL19386037 | 0.92 | USP30 (0.37) | USP30NR1H2RXRANR1H3CTSD | |
| SCHEMBL19602154 | 0.80 | USP30 (0.33) | USP30NR1H2RXRANR1H3USP2 | |
| SCHEMBL19401801 | 0.75 | MAPK1 (0.42) | CTSDALDH1A1MAPK1 | |
| SCHEMBL7875487 | 0.74 | ALDH1A1 (0.45) | USP30ALDH1A1 | |
| SCHEMBL19386033 | 0.74 | USP30 (0.34) | USP30NR1H2RXRANR1H3USP2 | |
| SCHEMBL19385984 | 0.74 | USP30 (0.34) | USP30NR1H2RXRANR1H3USP2 | |
| SCHEMBL19386032 | 0.74 | USP30 (0.34) | USP30NR1H2RXRANR1H3USP2 | |
| SCHEMBL29001363 | 0.70 | USP30 (0.33) | USP30USP2ALDH1A1CYP1A2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PSMA7, PSMA4, IL4 | USP30 2888/4885NR1H2 4101/4885RXRA 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.